CardioDx Inc. raised $57.5 million from equity and options investments, according to its latest filing with the Securities & Exchange Commission.

The Palo Alto, Calif.-based genomics firm is developing tests based on gene expression analysis to measure patients’ risk for cardiovascular diseases.

The new financing, which is part of the $78.3 million the company is trying to raise, was supported by 17 unnamed investors, according to the SEC filing.